Log In
BCIQ
Print this Print this
 

Bendeka, bendamustine (EP-3102)

Also known as: bendamustine RTD

  Manage Alerts
Collapse Summary General Information
Company Eagle Pharmaceuticals Inc.
DescriptionReady-to-dilute, 10-minute infusion formulation of bendamustine, an alkylating agent, requiring 50 mL saline or a mixture of sodium chloride and dextrose
Molecular Target DNA
Mechanism of Action 
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$120.0M

$30.0M

$90.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/17/2015

$120.0M

$30.0M

$90.0M

Get a free BioCentury trial today